Zealand Pharma announced positive Phase III trial results from Boehringer Ingelheim's survodutide, a glucagon/GLP-1 dual agonist, showing up to 34% visceral fat and 63% liver fat reduction in people with obesity, alongside up to 16.6% weight loss over 76 weeks. The SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials demonstrated that survodutide not only reduces weight but also targets metabolically harmful fat and improves liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). These results, presented at the American Diabetes Association 2026 Scientific Sessions and published in leading medical journals, highlight survodutide's potential as a novel treatment for obesity and related metabolic conditions. Zealand Pharma is eligible for royalties and milestone payments as Boehringer Ingelheim advances further Phase IIIb studies to optimize patient care and dosing.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
